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Lenalidomide is an immunomodulatory agent which has been approved for multiple myeloma. Lenalidomide is
also effective in and tolerated well by patients with follicular lymphoma, diffuse large B-cell lymphoma, and
transformed large cell lymphoma. This review summarizes the results of current preclinical and clinical studies of
lenalidomide, alone or in combination with the monoclonal antibody rituximab, as a therapeutic option for these
three lymphoma types. This review will serve as a tool guiding future clinical investigations to improve survival rates
for these three lymphomas.
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Originally used to treat morning sickness and aid sleep,
thalidomide was banned in the United States in the
1960s because it was linked to birth defects. But in 1999,
it was found to be effective in managing relapsed or
refractory multiple myeloma (MM) [1]. In 2006, after
thalidomide was shown to be effective in a large,
multicenter phase III trial, [2] the U.S. Food and Drug
Administration granted accelerated approval for its use in
newly diagnosed MM. But severe side effects including
neuropathy, thromboembolism, somnolence and fatigue,
as well as the emergence of resistance have limited its use
[3,4]. Attempts to find better and safer alternatives to
thalidomide have resulted in the development of a
novel class of structural analogues called immunomodula-
tors [5,6]. Immunomodulators, such as lenalidomide and
pomalidomide, possess a mechanism of action similar
to that of thalidomide but with more potent immune
enhancing actions [5]. Compared with thalidomide,
lenalidomide possesses an additional amino (NH2)
group at position 4 of the phthaloyl ring and loss of
the carbonyl (C = O) group at position 2.* Correspondence: kjnewber@mdanderson.org; miwang@mdanderson.org
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reproduction in any medium, provided the orLenalidomide has also shown activity in non-Hodgkin
lymphoma (NHL) in pivotal phase II clinical trials [7-9].
However, because these trials included many lymphoma
subtypes without sufficient statistical power for each
subtype, the activity of lenalidomide in specific NHL
subtypes was not well defined. To date, there has
been no collective review on lenalidomide in follicular
lymphoma (FL), diffuse large B-cell lymphoma
(DLBCL), or transformed large cell lymphoma (TmL).
Options are limited for these aggressive NHLs and
novel agents are needed to improve survival times. Here,
we review the results of recent preclinical and clinical
studies of lenalidomide in FL, DLBCL, and TmL, and
highlight potential insights to apply to future clinical
trials.Preclinical experience with lenalidomide
The precise mechanism of action of lenalidomide is not
known [10]. It inhibits tumor growth, induces apoptosis,
and directly kills tumor cells in B-cell NHL cell lines
[11,12]. Lenalidomide also increases peripheral blood
mononuclear cell activity, which can cause tumor cell
apoptosis [12]. It also enhances antibody-dependent cell-
mediated cytotoxicity (ADCC) and could partially over-
come rituximab resistance in rituximab-treated NHL cell
lines [13,14]. In addition, lenalidomide has significant
anti-angiogenic effects, including interactions with thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cular endothelial growth factor [15,16]. Lenalidomide can
effectively repair the immunological synapse dysfunction
induced by FL cells, thereby surpassing the immune-
evasion mechanisms of tumor cells [17]. Taken together,
lenalidomide possesses a diverse set of mechanism of ac-
tion in the tumor microenvironment (Figure 1).
Single-agent lenalidomide has been shown to be active
in B-cell lymphoma, [11,12] but data from preclinical
studies of DLBCL and FL are limited. Table 1 summa-
rizes the results from preclinical studies of lenalidomide
in DLBCL and FL cell lines. To date, there are no pub-
lished preclinical studies that have evaluated the activity
of lenalidomide specifically in patients with TmL.
Although the mechanism of action of lenalidomide has
been extensively studied, its precise molecular target was
undetermined until recently. In 2010, researchers discov-
ered that a cellular protein called cereblon (CRBN) is
associated with thalidomide’s teratogenicity and that
CRBN is also required for the anti-tumor effects of
lenalidomide and similar drugs, as well as the develop-
ment of resistance to this class of drugs [18,19]. When
CRBN is depleted, gene expression changes induced by
the drug are suppressed. Future trials should focus on the
possible role of CRBN as a biomarker for clinical
assessment of lenalidomide efficacy.
Rituximab is a monoclonal antibody against CD20 and
has shown activity in B-cell malignancies, which led to
its approval for treatment of many CD20+ B-cell NHL
[20]. Studies of B-cell lymphomas have shown that the
combination of lenalidomide and rituximab is indeed
effective and that it is a rational synergistic combinationFigure 1 Lenalidomide possesses a diverse set of mechanism of actio
growth inhibition, apoptosis induction, anti-tumor immune response, and a(Table 2) [13,21-24]. In 2005, Hernandez-Ilizaliturri et al.
reported that the lenalidomide-rituximab combination
inhibited cell growth and induced apoptosis in NHL cell
lines, including DLBCL cell lines (SU-DHL-4 and SU-
DHL-10), more than either agent alone [22]. This and
other studies have shown that lenalidomide increases NK
cell function and population, enhances NK cell- and
monocyte-mediated ADCC, alters the production of cyto-
kines by dendritic cells, and inhibits angiogenesis, which
all serve to increase the anti-tumor effects of rituximab
[13,22,23]. The lenalidomide-rituximab combination has
also shown synergistic effects in most of the NHL cell
lines tested. The lenalidomide-rituximab combination was
shown to reduce tumor burden and increase survival in B-
cell lymphoma (NHL)-bearing SCID mice [21,22].
Follicular lymphoma
FL is the most common indolent NHL [25,26]. The
World Health Organization grading system categorizes
FL into the following grades on the basis of morphologic
features, which correlate with the clinical course [27].
FLG1/2 is indolent in nature, while FLG3 [grade 3A and
3B] has a more aggressive course similar to DLBCL [28].
The majority of patients present with advanced-stage
disease and are not curable with standard chemotherapy
ultimately leading to disease relapse. FL has been charac-
terized by repeated responsiveness to treatment, but the
response is mostly partial and of short duration. Relapse
or transformation leads to death in most cases.
Promising results from preclinical studies and clinical
success with MM led investigators to design clinical tri-
als with lenalidomide as a single agent against NHL.n in the tumor microenvironment. These actions include direct
nti-angiogenesis.
Table 1 Preclinical studies with single-agent lenalidomide in NHL
Study Cell line Study findings
Gandhi et al. [11] Namalwa CSN.70 (Burkitt lymphoma)
cells
• Len inhibited proliferation of B-cell lymphoma cells and interfered with Gab1
phosphorylation and adaptor protein complex assembly.
Reddy et al. [14] Rtx-resistant cell lines created from Raji
(Burkitt lymphoma) cells
• Len improved Rtx anti-tumor activity and partially overcame Rtx resistance
by augmenting ADCC.
Verhelle et al. [50] Namalwa (Burkitt lymphoma) and
normal CD34+ progenitor cells
• Len plus pomalidomide inhibited proliferation of malignant B cells while
expanding population of normal CD34+ progenitor cells.
Zhu et al. [12] Raji (Burkitt lymphoma), K562 (CLL), PC-3
(prostate cancer), and PBMC cells
• Len plus pomalidomide induced apoptosis through NK cell activation.
Gaidarova et al. [51] MCL and PBMC (healthy donor) cells • Len enhanced anti-tumor effects of γδ T-cells against MCL.
Zhang LH et al. [52] MCL, DLBCL, and FL cells • Len induced direct anti-proliferative effects against each NHL subtype.
• Len inhibited high vascular endothelial growth factor levels seen in cell lines.
• These effects were associated with increased expression of tumor suppressor
proteins p21 and SPARC.
Escoubet-Losach
et al. [53]
Namalwa (Burkitt lymphoma) and LP-1
(MM) cells
• Len plus pomalidomide induced p21 WAF-1 expression in lymphoma and
MM through an LSD1-mediated epigenetic mechanism.
Ramsay et al. [17] FL, DLBCL, and TmL cells (fresh samples) • FL cells induced T-cell immunological synapse dysfunction that were
repaired with len.
Rtx = rituximab, CLL = chronic lymphocytic leukemia, PBMC = peripheral blood mononuclear cells, MCL =mantle cell lymphoma, FL = follicular lymphoma,
MM =multiple myeloma, TmL = transformed lymphoma, DLBCL = diffuse large B cell lymphoma, NHL = non-hodgkin lymphoma, ADCC = antibody-dependent
cell-mediated cytotoxicity.
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001, NHL-002, NHL-003, studied the activity and toler-
ability of single-agent lenalidomide in relapsed or re-
fractory B-cell NHL. In all three clinical trials, oral
lenalidomide at a dose of 25 mg was self-administered
for days 1–21 of each 28-day cycle. These trials stratifiedTable 2 Preclinical studies with the combination of lenalidom
Study Cell line In vivo mod
Hernandez-Ilizaliturri
et al. [22]
Raji (Burkitt lymphoma) and SU-DHL
-4 and SU-DHL-10 (DLBCL) cells
SCID mouse
(Burkitt Lymp
Wu et al. [13] Raji and Namalwa (Burkitt
lymphoma), Farage (DLBCL), Jeko-1
(MCL), and primary B-CLL cells
-
Reddy et al. [23] Raji (Burkitt lymphoma) cells SCID mouse
(Burkitt Lymp
Gaidarova et al. [54] Jeko-1 (MCL) cells -
Gandhi et al. [55] DoHH-2 (FL), Rec-1 (MCL), Farage
(DLBCL), and fresh FL cells
Zhang et al. [21] SP53, MINO, Grant 519 cells (MCL)
and fresh patient samples (MCL)
SCID mouse
Gaidarova et al. [56] Jeko-1 (MCL) and B-CLL cells -
Len = lenalidomide, Rtx = rituximab, MCL =mantle cell lymphoma, FL = follicular lym
leukemia, NK cells = Natural Killer cells, ADCC = antibody-dependent cell-mediated cthe response data by NHL subtype and response rates
are presented in Table 3.
NHL-001 was a phase II, single-arm, multicenter study
which enrolled 43 patients with indolent NHL, including
22 patients with FLG1/2 [9]. FLG1/2 patients had received
a median of 3 (range, 1–17) prior systemic therapies. Anide and rituximab in NHL
el Study findings
homa)
• Len augmented NK cell function and increased anti-tumor
effects of Rtx against B-cell lymphomas.
• Len-Rtx enhanced anti-tumor activity in SCID-mouse
lymphoma model.
• Len enhanced NK cell- and monocyte-mediated ADCC of
Rtx-treated CD20+ tumor cells.
• Len has strong potential to enhance Rtx-mediated killing of
NHL cell lines.
homa)
• Len-Rtx enhanced anti-tumor effects.
• These effects were caused by modulation of the immune
system mediated by dendritic cells and NK cells, which changed
the cytokine milieu, and by their anti-angiogenic effects.
• Len-Rtx treatment of MCL cells enhanced NK cell-mediated
synapse formation and cell killing.
• Len-Rtx induced anti-proliferative and anti-apoptotic effects in
FL cells in vitro and in vivo through Bcl-2 activation.
(MCL) • Len-Rtx had a synergistic therapeutic effect on MCL cells by
enhancing apoptosis and Rtx-dependent NK cell-mediated
cytotoxicity.
• Len-Rtx decreased tumor burden and prolonged survival of
MCL-bearing SCID mice.
• Len induced capping of CD20 and cytoskeletal proteins to
enhance Rtx immune recognition of malignant B-cells.
phoma, DLBCL = diffuse large B-cell lymphoma, CLL = chronic lymphocytic
ytotoxicity.
Table 3 Clinical trials with single-agent lenalidomide (25 mg, days 1–21) against FL, DLBCL, and TmL
Study No. of
patients
ORR CR/uCR PR MDRǂ PFSǂ OSǂ F/Uǂ Most common
adverse events (grade 3 & 4)*
Untreated FLG1/2
Single agent lenalidomide has not been studied for initial therapy of FLG1/2.
Relapsed or refractory FLG1/2
NHL-001: 22 27 9 18 >16.5* 4.4* N/A 4.4* Neutropenia (30% & 16%)
Witzig et al. [9] Thrombocytopenia (14% & 5%)
Untreated FLG3
Single agent lenalidomide has not been studied for initial therapy of FLG3.
Relapsed or refractory FLG3
NHL-002: 5 60 0/20 40 6.2* 4* N/A 3.7* Neutropenia (24.5% & 8.2%)
Wiernik et al. [7] Thrombocytopenia (12.2% & 8.2%)
NHL-003 19 42 11 32 NR 8.9 N/A 9.2* Neutropenia (41%)
Witzig et al. [8] Thrombocytopenia (19%)
Untreated DLBCL
Single agent lenalidomide has not been studied for initial therapy of DLBCL.
Relapsed or refractory DLBCL
NHL-002: 26 19 4/8 8 6.2* 4* N/A 3.7* Neutropenia (24.5% & 8.2%)
Wiernik et al. [7] Thrombocytopenia (12.2% & 8.2%)
NHL-003 108 28 7 20 4.6 2.7 N/A 9.2* Neutropenia (41%)
Witzig et al. [8] Thrombocytopenia (19%)
Untreated TmL
Single agent lenalidomide has not been studied for initial therapy of TmL.
Relapsed or refractory TmL
NHL-002: 3 33 0 33 6.2* 4* N/A 3.7* Neutropenia (24.5% & 8.2%)
Wiernik et al. [7] Thrombocytopenia (12.2% & 8.2%)
NHL-003: 33 45 21 24 12.8 5.4 N/A 9.2* Neutropenia (41%)
Witzig et al. [8] Thrombocytopenia (19%)
*Value is for whole study group.
ǂMedian values are shown in months.
N/A = data not available, OS = overall survival, PFS = progression free survival, DR = duration of response, FL = follicular lymphoma, TmL = transformed lymphoma,
ORR = overall response rate, CR = complete response, uCR = unconfirmed CR, PR = partial response, F/U = follow-up period.
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CR. The median progression-free survival time (PFS) for
the FLG1/2 group was not reported, but the median PFS
time for all 43 patients enrolled in the study was
4.4 months (range, 2.5-10.4 months). The most common
grades 3 and 4 hematological toxicities were neutropenia
(30% and 16%) and thrombocytopenia (14% and 5%).
NHL-002 was a phase II single-arm study conducted
at multiple centers in the U.S. and enrolled 49 patients
with relapsed or refractory aggressive NHL (FLG3,
DLBCL, TmL, and mantle cell lymphoma [MCL]). Pa-
tients had received a median of 4 (range, 1 to ≥ 5) prior
treatment regimens [7]. The ORR for all patients was
35%; the partial response (PR) rate was 22% and the
CR/unconfirmed CR (CRu) rate was 12%.%). In the NHL-
002 trial, three (60%) of the five patients with relapsed
and/or refractory FLG3 achieved a response, one (20%)
of which was an unconfirmed CR [7]. The median PFSduration was 4 months (range, 0–14.5 months), and the
median follow-up time was 3.7 months (range, 0–
12.8 months). Grade 4 adverse events were neutropenia
(8.2%) and thrombocytopenia (8.2%). The most com-
mon grade 3 adverse events were neutropenia (24.5%),
leukopenia (14.3%), and thrombocytopenia (12.2%).
After the initial promising data from these small trials, a
larger international phase II, single-arm, open-label study
of lenalidomide in 217 patients with biopsy-proven re-
lapsed or refractory aggressive DLBCL, FLG3, TmL, or
MCL was initiated (NHL-003). In the NHL-003 trial, 217
patients had received a median of 3 (range, 1–13) prior
treatment regimens [8]. The ORR was 35%; the PR rate
was 22% and the CR/CRu rate was 13%. The median PFS
was 3.7 months, and the median follow-up period was
9.2 months. The most common grade 3 or 4 adverse
events were neutropenia (41.0%), thrombocytopenia
(19.0%), and anemia (9.2%). In the NHL-003 trial,
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response, two (11%) of whom achieved CR; the me-
dian PFS duration in this trial was 8.9 months.9
Despite preclinical evidence of the synergistic activity
and enhanced anti-tumor efficacy of the lenalidomide–
rituximab combination, clinical studies testing this
regimen in FL, DLBCL and TmL are limited. Published
clinical data on this novel combination in patients with
FL, DLBCL, or TmL are summarized in Table 4 and
discussed below.
Fowler et al. recently reported promising efficacy and
tolerability data with lenalidomide plus rituximab in un-
treated indolent NHL from a single-center phase II trial
[29]. Patients were not stratified for World Health
Organization grading of FL. Forty-six patients with pre-
viously untreated, advanced stage FL had a high ORR of
96% and a CR rate of 87%. The PFS rate at the end of
2 years was 89% after a median follow up of 22 months.
There was a low incidence of adverse events; the most sig-
nificant grade 3 or 4 event was neutropenia (40%) [30].
Thrombocytopenia was seen in 4% of patients. The most
common grade 3/4 non-hematological adverse events
were: rash (7%) and muscle pain (6%). These findings
indicate a highly promising role for the lenalidomide-
rituximab combination as a front-line regimen against
FL. Immunophenotyping and gene expression profiling
(GEP) of peripheral blood samples from FL patients at
baseline and end of cycle 6 from this study showed that
lenalidomide can induce multiple changes in the immune
system including down-regulation of certain genes medi-
ating B cell migration and proliferation [31].
Dutia et al. were the first to report promising activity
of the lenalidomide-rituximab combination for relapsed
or refractory FL [32]. For the 16 patients in that study
the ORR was 86%, and 8/16 had CR. The median PFS
duration was 13 months. Lymphopenia (25%), neutro-
penia (19%) and hyponatremia (19%) were significant
grade 3 or 4 adverse events. Stratified responses for FL
subtypes are not available. Leonard et al. directly com-
pared single-agent lenalidomide to the lenalidomide-
rituximab combination in recurrent FL in a phase II ran-
domized controlled trial (CALGB 50401) [33]. In both
treatment arms, patients were treated with 15 mg of
lenalidomide in cycle 1 (on days 1–21 of a 28-day cycle)
followed by 20 mg of lenalidomide during cycles 2–12.
In the lenalidomide-only arm, which consisted of 45
patients, the ORR was 49% with an event-free survival
duration of 1.2 years. Significant grade 3 or 4 toxicities
were neutropenia (16%) thrombosis (16%), and fatigue
(9%). In the lenalidomide-rituximab arm, which consisted
of 44 patients, the addition of 375 mg/m2 rituximab once
weekly for 4 weeks increased the ORR to 75% and the
event-free survival time to 2 years. Slightly more grade 3
or 4 neutropenia (19%) and fatigue (14%) was observedbut less thrombosis (4%) than in the lenalidomide-only
arm [33]. Thus, compared with lenalidomide alone, the
lenalidomide-rituximab combination was more effective
without significantly more toxicity against relapsed or
refractory FL.
Highly promising activity has been reported in un-
treated, advanced FL as well as in recurrent, relapsed FL,
but because FL patients were not stratified by WHO grad-
ing in these trials, it is not possible to determine whether
there are differences in the activity of lenalidomide-
rituximab between those with indolent (FLG1/2) and
aggressive disease (FLG3) [30,33]. Our group recently
published the results of a single-center phase II trial using
lenalidomide plus rituximab for 45 NHL patients, includ-
ing four with FLG3 [34]. In that trial, only one patient
with FLG3 achieved a partial response (25%). The median
overall survival duration was 25.6 months, which was the
highest among all the NHL subtypes in this study [34]. Be-
cause lenalidomide alone can elicit an ORR of 42-60% in
patients with relapsed or refractory FLG3 [7,8], the
addition of the monoclonal antibody rituximab might have
been expected to elicit a higher response rate; however,
given the small sample size it is hard to draw any conclu-
sions. Because FLG3 is a rare lymphoma, multi-center
international trials will be necessary to gauge the actual
activity of this combination in these patients.
Diffuse large b-cell lymphoma
DLBCL is the most common subtype of NHL [25,26]. It
is divided into three major categories based on gene ex-
pression signatures: activated B-cell-like (ABC), germinal
center B-cell-like (GCB), and primary mediastinal B-cell
lymphoma (PMBL) [35,36]. The genetic differences
might be responsible for their different rates of response
to chemotherapy. More than one-third of patients re-
lapse or become refractory to standard chemotherapy
[37]. Even with the best second-line agents, the 3-year
EFS remains low (21%) [38]. Relapse or progressive dis-
ease (refractory) is a major cause of death in DLBCL pa-
tients. In brief, novel agents are sorely needed for this
NHL subtype.
Single-agent lenalidomide has shown activity in clin-
ical trials to. There were 26 patients with relapsed or re-
fractory DLBCL in the NHL-002 trial. The ORR was
19% and the CR rate was 4% (uCR 8%) [7]. In the NHL-
003 trial, which enrolled 108 patients with relapsed or
refractory DLBCL, the ORR was 28% and the CR rate
was 8% [8]. In the latter trial, the median PFS for
DLBCL patients was 2.7 months and the median re-
sponse duration was 4.6 months.
There is a lack of conclusive data regarding the clinical
response of DLBCL subtypes to lenalidomide as a single
agent or in combination with chemotherapy. Hernandez-
Ilizaliturri et al. investigated the activity of single-agent
Table 4 Clinical trials with the combination of lenalidomide and rituximab against FL, DLBCL, and TmL






Median DR Median PFS Median OS Median F/U Most common
adverse events (grade 3 & 4)*
Untreated FL (not stratified)
Fowler et al. [29,30] Len: 20 mg, D1-21 46 98 87 11 N/A 2-yr PFS* 89% N/A 22 months Neutropenia (40%)
Rtx: 375 mg/m2, D1 Thrombocytopenia (4%)
Relapsed or refractory FL (not stratified)
Dutia et al. [32] Len: 20 mg, D1-21 16 86 50 36 N/A 13 months* N/A 9 months* Lymphopenia (25%)
Rtx: 375 mg/m2, D15 of C1, 1/wk × 4 Neutropenia (19%)
Hyponatremia (19%)
Wang et al. [34] [only
FLG3]
Len: 20 mg, D1-21 4 25 0 25 10.2 months* 2.0 months 25.6 months 24.6 months* Neutropenia (31% & 22%)
Rtx: 375 mg/m2, Thrombocytopenia (18% and 16%)
1/wk × 4, only C1
Leonard et al. [33] Len: 15 mg C1; 45 49 13 36 N/A EFS 1.2 years N/A 1.5 years Neutropenia (16%)
20 mg C2-12, D1-21 Thrombosis (16%)
Fatigue (9%)
Len: 15 mg C1; 44 75 32 43 N/A EFS 2.0 years N/A 1.5 years Neutropenia (19%)
20 mg C2-12, D1-21 Fatigue (14%)
Rtx: 375 mg/m2,, 1/wk × 4 Thrombosis (4%)
Untreated DLBCL
Lenalidomide plus rituximab combination as a front-line therapy has not been studied for untreated DLBCL.
Relapsed or refractory DLBCL
Zinzani et al. [41] Len: 20 mg, D1-21, 23 35 35 0 N/A 1-yr DFS 34.8% 18-month
OS 55%
16 months Neutropenia (30%)
Rtx: 375 mg/m2, D1-21 (during
induction)
Thrombocytopenia (14%)
Wang et al. [34] Len: 20 mg, D1-21 32 28 22 6 10.2 months* 2.8 months 10.2 months 24.6 months* Neutropenia (31% & 22%)
Rtx: 375 mg/m2; Thrombocytopenia (18% and 16%)
1/wk × 4, only C1
Untreated TmL
Lenalidomide plus rituximab combination as a front-line therapy has not been studied for untreated TmL.
Relapsed or refractory TmL
Wang et al. [34] Len: 20 mg, D1-21 9 56 33 22 10.2 months* 4.3 months 11.5 months 24.6 months* Neutropenia (31% & 22%)
Rtx: 375 mg/m2.
1/wk × 4, only C1 Thrombocytopenia (18% and 16%)
*Value is for whole study group.
D = day, C = cycle, FL = follicular lymphoma, N/A = data not available, NHL = non-Hodgkin lymphoma, R/R = relapsed or refractory, Len = lenalidomide, Rtx = rituximab, EFS = event-free survival, OS = overall survival,
PFS = progression-free survival, DR = duration of response, FL = follicular lymphoma, TmL = transformed lymphoma, CR = complete response, uCR = unconfirmed CR, PR = partial response, ORR = overall response rate,
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was stratified into GCB-like (n = 23) and non-GCB-like
subtypes (n = 17) according to the Hans algorithm [39]. In
that study, lenalidomide was more effective in treating
non-GCB-like DLBCL (mainly the activated B-cell-like
variant) than GCB-like DLBCL (ORR, 52.9% vs. 8.7%). Re-
cently, Zhang et al. found that lenalidomide has direct
antitumor activity against DLBCL cells, which is mediated
by blocking IRF-4 expression and the BCR-NF-kB sig-
naling pathway in a cereblon dependent manner [40].
Lenalidomide was found to preferentially suppress
proliferation of ABC-DLBCL cells in vitro and delay
tumor growth in a human tumor xenograft model with
minimal effect on non-ABC-DLBCL cells. In order to
more accurately define DLBCL subtypes and those pa-
tients who respond to lenalidomide, future trials enrolling
DLBCL patients should stratify them on the basis of major
subtypes based on gene signatures to assess whether cell
of origin (COO) and clinical response are associated. This
will allow us to identify the population that can derive the
most benefit from lenalidomide.
Although the lenalidomide-rituximab combination has
shown considerable activity in preclinical studies, to date,
only 2 clinical studies have tested this combination in re-
lapsed or refractory DLBCL. Zinzani et al. reported the re-
sults of a phase II clinical trial testing the combination in
a group of 23 elderly patients (≥ 65 years) with relapsed or
refractory DLBCL [41]. Patients were treated with oral
lenalidomide (20 mg/day for 21 days of each 28-day cycle)
and rituximab (375 mg/m2 on days 1 and 21 of each 28-
day cycle) for 4 cycles followed by a maintenance phase
with lenalidomide only for another 8 months. The median
number of prior therapies was 3 (range, 2–8). A CR was
achieved in 8 patients (35%) at the end of the maintenance
phase. The 1-year disease-free survival (DFS) rate was
35%, and the 18-month overall survival rate was 55%. The
most common grade 3 or 4 adverse events were neutro-
penia (30%) and thrombocytopenia (14%) [41].
Our recently completed trial included 32 patients with
relapsed or refractory DLBCL [34]. The patients received
20 mg of oral lenalidomide on days 1–21 of each 28-day
cycle and intravenous rituximab (375 mg/m2) for 4
weekly doses during the first cycle. The median number
of prior lines of therapy was 3 (range, 1–4), and the
median follow-up time was 24.6 months (range, 12.4-
43.7 months). The ORR was 28%, and the CR rate was
22%. The median overall survival time was 10.2 months.
The most common grade 3–4 hematological toxicities
for the whole study population were neutropenia (53%)
and thrombocytopenia (34%).
Compared with the clinical data for single-agent
lenalidomide in relapsed or refractory DLBCL, for which
4-8% patients achieved CR, [7,8] these two clinical
studies using the lenalidomide-rituximab combinationreported a substantially higher proportion of patients
achieving a CR (28-35%) [34,41]. The findings are quite
promising, and the lenalidomide-rituximab combination
should be studied further in a larger population of pa-
tients with relapsed or refractory DLBCL.
Lenalidomide as a single agent as well as in combin-
ation with rituximab can be a good alternative as a
maintenance regimen once CR is achieved with high
dose chemotherapy or following ASCT. One such study
demonstrated lenalidomide as a maintenance therapy
has promising clinical activity following standard chemo-
therapy R-CHOP and resulted in superior survival out-
comes in DLBCL patients with high risk prognostic
features (IPI ≥ 3). The 2-year PFS and DFS were 92% and
100%, respectively, for those who received lenalidomide
maintenance (25 mg/day for 21 days of 28-cycle) for one
year [42]. Survival rates were slightly lower with the
lenalidomide-rituximab combination than with single agent
lenalidomide. Larger studies comparing maintenance regi-
mens may shed light on this disparity; still, it is enough to
conclude that lenalidomide is a good tolerable strategy for
keeping patients relapse-free once CR is achieved.
Nowakowski et al. tested adding lenalidomide to con-
ventional R-CHOP chemotherapy for frontline treatment
of aggressive B-cell lymphomas, including DLBCL and
FLG3. The phase I study demonstrated that 25 mg
lenalidomide give on days 1–10 of the cycle can be com-
bined with R-CHOP without the addition of significant
toxicity [43]. A phase II study showed that addition of
lenalidomide to R-CHOP is an effective and safe option
for initial therapy of patients with DLBCL and FLG3 [44].
There were 47 patients with newly diagnosed DLBCL and
4 with newly diagnosed FLG3. The ORR and CR rates
were 98% and 83%. The PFS was 73% at the end of 1-year.
The most common hematological toxicities were grade 3
and 4 thrombocytopenia (20% and 20% of patients, re-
spectively) and grade 3 and 4 neutropenia (18% and 71%
of patients, respectively). This study provided pivotal evi-
dence for further studying the combination of R-CHOP
and lenalidomide for newly diagnosed aggressive B-cell
lymphomas.
Transformed large cell lymphoma
When an indolent lymphoma turns into an aggressive,
rapidly progressive lymphoma both clinically and micro-
scopically, it is defined as a TmL [45]. Any indolent B-
or T-cell lymphoma can transform, but FL is the most
likely to [46,47]. Indolent FL can undergo transform-
ation to become DLBCL, Burkitt lymphoma, or (rarely)
lymphoblastoid lymphoma. The risk of FL transform-
ation is 3% per year after initial diagnosis with a very
short post-transformation survival (1.7-2.7 years) [45,48].
Management of TmL is challenging and there is no
standard approach for treatment.
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http://www.jhoonline.org/content/6/1/55Because TmL is a rare form of lymphoma, clinical data
on the activity of lenalidomide are limited. Three pa-
tients were enrolled in the NHL-002 study, 1 of whom
(33%) achieved a PR [7]. The NHL-003 trial included 33
TmL patients, with 15 (45%) achieving a response, and
among those, 7 (21%) achieved a CR [8]. The median
PFS was 5.4 months, and the median follow-up time was
9.2 months. In a separate sub-analysis of the 33 patients
with TmL in the NHL-003 study, Czuczman et al. found
lenalidomide was effective for patients with transformed
FL (ORR, 56.5%) but not those with transformed chronic
or small lymphocytic lymphoma (ORR, 0%) [49]. Larger
trials with stratified histological subtype analyses are re-
quired to validate those findings.
To date, there has been limited experience with the
use of the lenalidomide-rituximab combination in TmL.
Since single-agent lenalidomide has been shown to be
effective against TmL8,9 and rituximab [20] has been
shown to be effective against all aggressive NHLs studied
to date, this combination may well be effective against
TmL. Our recent study included nine patients with pre-
viously treated TmL [34]. The ORR was 56%, and the
CR rate was 33% with a median OS of 11.5 months.
These findings are promising but further investigation in
a large-scale, multicenter, international trial of the
lenalidomide-rituximab combination in patients with re-
lapsed or refractory TmL is necessary.Conclusion
In conclusion, novel agents with enhanced efficacy and
fewer side effects are needed for patients with relapsed
and/or refractory DLBCL, FL and TmL, the most com-
mon of NHL subtypes. Lenalidomide is a good candidate
agent due to its unique immunomodulatory properties,
ability to prolong patient survival, and good safety profile.
Many clinical trials have been designed and are enrolling
patients to assess the activity and safety of frontline, main-
tenance, or salvage lenalidomide —alone, with rituximab,
or with other agents — against FL, DLBCL, and TmL.
Randomized controlled clinical trials of lenalidomide as a
single agent and in combination with rituximab and other
targeted therapies should be conducted with larger popu-
lations stratified by disease subtype and gene expression
profiles to confirm the initial findings and to move
lenalidomide into the growing arsenal of frontline
therapies for aggressive NHLs.Competing interests
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